An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3037-3057

  Yang, Kyunghee ^a   Köck, Kathleen ^a   Sedykh, Alexander ^a   Tropsha, Alexander ^a   Brouwer, Kim L R ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Bile acid; Drug induced cholestasis; in silico modeling; Pharmacokinetic parameters; Physicochemical properties; Transporters

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; BILIRUBIN; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROPAMIDE; CIPROFLOXACIN; CLINDAMYCIN; CROMOGLYCATE DISODIUM; CYPROHEPTADINE; DEXTROPROPOXYPHENE; DIAZEPAM; FLOXURIDINE; FLUCLOXACILLIN; GAMMA GLUTAMYLTRANSFERASE; HALOPERIDOL; IBUPROFEN; IMIPRAMINE; METHYLTESTOSTERONE; PHENYLBUTAZONE; PHENYTOIN; PIOGLITAZONE; PROCHLORPERAZINE; TENOXICAM; TERBINAFINE; TETRACYCLINE; TIABENDAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN; UNINDEXED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE DUCT INJURY; BILE FLOW; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; CHOLELITHIASIS; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; COMPUTER MODEL; CONJUGATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SOLUBILITY; ENTEROHEPATIC CIRCULATION; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; INFLAMMATION; INTESTINE ABSORPTION; JAUNDICE; LIPOPHILICITY; LIVER CELL; LIVER CELL DAMAGE; LIVER INJURY; MALAISE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NAUSEA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRURITUS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCLEROSING CHOLANGITIS; TOXICITY; URINARY EXCRETION; XANTHOMA;

BILE ACID; DRUG-INDUCED CHOLESTASIS; IN SILICO MODELING; PHARMACOKINETIC PARAMETERS; PHYSICOCHEMICAL PROPERTIES; TRANSPORTERS;

ANIMALS; BILE ACIDS AND SALTS; BILE DUCTS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHOLESTASIS; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84881616816     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23584     Document Type: Article

References (161)

1. Lee WM. 2003. Drug-induced hepatotoxicity. N Engl J Med 349(5):474-485.
2. Benichou C. 1990. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11(2):272-276.
3. Bjornsson E, Olsson R. 2005. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42(2):481-489.
4. Friis H, Andreasen PB. 1992. Drug-induced hepatic injury: An analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 232(2):133-138.
5. Lewis JH. 2000. Drug-induced liver disease. Med Clin North Am 84(5):1275-1311, x.
6. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. 2011. Drug-induced cholestasis. Hepatology 53(4):1377-1387.
7. Viteri AL, Greene JF, Jr., Dyck WP. 1979. Erythromycin ethylsuccinate-induced cholestasis. Gastroenterology 76(5 Pt 1):1007-1008.
8. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M. 1994. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 20(6):1437-1441.
9. Erlinger S. 1997. Drug-induced cholestasis. J Hepatol 26 Suppl 1:1-4.
10. Geubel AP, Sempoux C, Rahier J. 2003. Bile duct disorders. Clin Liver Dis 7(2):295-309.
11. Russell DW. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137-174.
12. Norlin M, Wikvall K. 2007. Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med 7(2):199-218.
13. Chiang JY. 2009. Bile acids: Regulation of synthesis. J Lipid Res 50(10):1955-1966.
14. Hofmann AF. 1994. Bile Acids. In The liver: Biology and pathobiology. New York: Raven Press Limited.
15. Reichen J, Paumgartner G. 1976. Uptake of bile acids by perfused rat liver. Am J Physiol 231(3):734-742.
16. Van Dyke RW, Stephens JE, Scharschmidt BF. 1982. Bile acid transport in cultured rat hepatocytes. Am J Physiol 243(6):G484-G492.
17. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. 1998. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther 286(2):1043-1050.
18. Marion TL, Perry CH, St Claire RL, 3rd, Yue W, Brouwer KL. 2011. Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes. Toxicol Sci 120(2):371-380.
19. Agellon LB, Torchia EC. 2000. Intracellular transport of bile acids. Biochim Biophys Acta 1486(1):198-209.
20. El-Seaidy AZ, Mills CO, Elias E, Crawford JM. 1997. Lack of evidence for vesicle trafficking of fluorescent bile salts in rat hepatocyte couplets. Am J Physiol 272(2 Pt 1):G298-G309.
21. Pauli-Magnus C, Meier PJ. 2006. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44(4):778-787.
22. Rost D, Konig J, Weiss G, Klar E, Stremmel W, Keppler D. 2001. Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology 121(5):1203-1208.
23. Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N. 2005. OSTalpha-OSTbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42(6):1270-1279.
24. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y. 2002. Transport activity of human MRP3 expressed in Sf9 cells: Comparative studies with rat MRP3. Pharm Res 19(1):34-41.
25. Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D. 2006. Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 290(4):G640-G649.
26. Ballatori N. 2005. Biology of a novel organic solute and steroid transporter, OSTalpha-OSTbeta. Exp Biol Med (Maywood) 230(10):689-698.
27. Ballatori N, Li N, Fang F, Boyer JL, Christian WV, Hammond CL. 2009. OST alpha-OST beta: A key membrane transporter of bile acids and conjugated steroids. Front Biosci 14:2829-2844.
28. Akita H, Suzuki H, Sugiyama Y. 2001. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm Res 18(8):1119-1125.
29. Trauner M, Wagner M, Fickert P, Zollner G. 2005. Molecular regulation of hepatobiliary transport systems: Clinical implications for understanding and treating cholestasis. J Clin Gastroenterol 39(4 Suppl 2):S111-S124.
30. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. 2007. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 27(7):920-929.
31. Teng S, Piquette-Miller M. 2007. Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 151(3):367-376.
32. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. 2006. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290(6):G1124-G1130.
33. Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. 2004. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279(21):22250-22257.
34. Alnouti Y. 2009. Bile acid sulfation: A pathway of bile acid elimination and detoxification. Toxicol Sci 108(2):225-246.
35. Hofmann AF. 1999. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159(22):2647-2658.
36. Dietschy JM. 1968. Mechanisms for the intestinal absorption of bile acids. J Lipid Res 9(3):297-309.
37. Shneider BL. 2001. Intestinal bile acid transport: Biology, physiology, and pathophysiology. J Pediatr Gastroenterol Nutr 32(4):407-417.
38. Hagenbuch B, Dawson P. 2004. The sodium bile salt cotransport family SLC10. Pflugers Arch 447(5):566-570.
39. Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, Ballatori N. 2005. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 280(8):6960-6968.
40. Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, Dawson PA. 2008. The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci USA 105(10):3891-3896.
41. Trauner M, Boyer JL. 2003. Bile salt transporters: Molecular characterization, function, and regulation. Physiol Rev 83(2):633-671.
42. Ming X, Thakker DR. 2010. Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. Biochem Pharmacol 79(3):455-462.
43. Jonker JW, Liddle C, Downes M. 2012. FXR and PXR: Potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 130(3-5):147-158.
44. Claudel T, Staels B, Kuipers F. 2005. The Farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25(10):2020-2030.
45. Perez MJ, Briz O. 2009. Bile-acid-induced cell injury and protection. World J Gastroenterol 15(14):1677-1689.
46. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. 1998. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 101(12):2790-2799.
47. Roberts LR, Kurosawa H, Bronk SF, Fesmier PJ, Agellon LB, Leung WY, Mao F, Gores GJ. 1997. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology 113(5):1714-1726.
48. Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, Zatloukal K, Jaeschke H, Denk H, Trauner M. 2006. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 168(2):410-422.
49. Salvioli G, Lugli R, Pradelli JM, Gigliotti G. 1985. Bile acid binding in plasma: The importance of lipoproteins. FEBS Lett 187(2):272-276.
50. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. 2009. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 4:1.
51. Dixon PH, van Mil SW, Chambers J, Strautnieks S, Thompson RJ, Lammert F, Kubitz R, Keitel V, Glantz A, Mattsson LA, Marschall HU, Molokhia M, Moore GE, Linton KJ, Williamson C. 2009. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 58(4):537-544.
52. Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, Tanaka H, Arias IM, Mine T. 2008. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol 294(1):G58-G67.
53. Lee JK, Paine MF, Brouwer KL. 2010. Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. J Pharmacol Exp Ther 334(2):410-418.
54. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69(4):223-231.
55. Bohme M, Muller M, Leier I, Jedlitschky G, Keppler D. 1994. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology 107(1):255-265.
56. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R. 2001. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167(1):83-98.
57. Kis E, Ioja E, Nagy T, Szente L, Heredi-Szabo K, Krajcsi P. 2009. Effect of membrane cholesterol on BSEP/Bsep activity: Species specificity studies for substrates and inhibitors. Drug Metab Dispos 37(9):1878-1886.
58. Mano Y, Usui T, Kamimura H. 2007. Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28(1):13-18.
59. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Jr., Lightfoot-Dunn R, Hamadeh HK. 2010. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 118(2):485-500.
60. Dawson S, Stahl S, Paul N, Barber J, Kenna JG. 2012. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40(1):130-138.
61. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. 2000. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118(2):422-430.
62. Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, Elferink RP, Housset C. 2002. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 37(2):184-191.
63. van Erpecum KJ. 2005. Biliary lipids, water and cholesterol gallstones. Biol Cell 97(11):815-822.
64. Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. 2009. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci 14:4242-4256.
65. Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, Yokota H, Yatomi Y, Yoshida H, Goto J, Tsuji S, Suzuki H. 2011. Itraconazole-induced cholestasis: Involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 79(2):241-250.
66. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P. 2000. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275(31):23530-23539.
67. Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. 2004. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 40(4):585-591.
68. Wang R, Sheps JA, Ling V. 2011. ABC transporters, bile acids, and inflammatory stress in liver cancer. Curr Pharm Biotechnol 12(4):636-646.
69. Keitel V, Burdelski M, Warskulat U, Kuhlkamp T, Keppler D, Haussinger D, Kubitz R. 2005. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41(5):1160-1172.
70. Chai J, Luo D, Wu X, Wang H, He Y, Li Q, Zhang Y, Chen L, Peng ZH, Xiao T, Wang R, Chen W. 2011. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. J Gastrointest Surg 15(6):996-1004.
71. Soroka CJ, Lee JM, Azzaroli F, Boyer JL. 2001. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33(4):783-791.
72. Donner MG, Keppler D. 2001. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 34(2):351-359.
73. Yang K, Yue W, Koeck K, Pfeifer ND, Brouwer KLR. 2011. Interaction of troglitazone sulfate with hepatic basolateral and canalicular transport proteins. 2011 AAPS Annual Meeting and Exposition, Washington, DC, p M1301.
74. Köck K, Ferslew BC, Yang K, Brouwer KLR. 2011. Inhibition of hepatic bile acid transporter MRP4: A potential risk factor for drug-induced liver injury (DILI). SOT Annual Meeting and ToxExpo. San Francisco, California, p 495.
75. Köck K, Ferslew B, Netterberg I, Yang K, Urban T, Swaan P, Brouwer KLR. 2012. Inhibition of the hepatic basolateral bile acid transporter MRP4 predicts cholestatic drug-induced liver injury (DILI). AASLD Liver Meeting. Boston, Massachusetts.
76. +-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: A mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321(3):1170-1178.
77. Marion TL, Leslie EM, Brouwer KL. 2007. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4(6):911-918.
78. Ansede JH, Smith WR, Perry CH, St Claire RL, 3rd, Brouwer KR. 2010. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab Dispos 38(2):276-280.
79. Kemp DC, Zamek-Gliszczynski MJ, Brouwer KL. 2005. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 83(2):207-214.
80. Trottier J, Caron P, Straka RJ, Barbier O. 2011. Profile of serum bile acids in noncholestatic volunteers: Gender-related differences in response to fenofibrate. Clin Pharmacol Ther 90(2):279-286.
81. Miyazaki K, Nakayama F, Koga A. 1984. Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes. Dig Dis Sci 29(12):1123-1130.
82. Jung D, Inagaki T, Gerard RD, Dawson PA, Kliewer SA, Mangelsdorf DJ, Moschetta A. 2007. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res 48(12):2693-2700.
83. Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loret-de-Mola O, Nahmad M, Burnweit CA. 1998. Ileal exclusion for Byler's disease: An alternative surgical approach with promising early results for pruritus. J Pediatr Surg 33(2):220-224.
84. Emond JC, Whitington PF. 1995. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J Pediatr Surg 30(12):1635-1641.
85. Whitington PF, Whitington GL. 1988. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 95(1):130-136.
86. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. 2005. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 102(6):2063-2068.
87. Beilke LD, Aleksunes LM, Holland RD, Besselsen DG, Beger RD, Klaassen CD, Cherrington NJ. 2009. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab Dispos 37(5):1035-1045.
88. Zollner G, Marschall HU, Wagner M, Trauner M. 2006. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol Pharm 3(3):231-251.
89. Geier A, Wagner M, Dietrich CG, Trauner M. 2007. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 1773(3):283-308.
90. Madhu C, Maziasz T, Klaassen CD. 1992. Effect of pregnenolone-16 alpha-carbonitrile and dexamethasone on acetaminophen-induced hepatotoxicity in mice. Toxicol Appl Pharmacol 115(2):191-198.
91. Seo KW, Park M, Kim JG, Kim TW, Kim HJ. 2000. Effects of benzothiazole on the xenobiotic metabolizing enzymes and metabolism of acetaminophen. J Appl Toxicol 20(6):427-430.
92. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM, Downes M. 2006. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 103(30):11323-11328.
93. Renga B, Migliorati M, Mencarelli A, Cipriani S, D'Amore C, Distrutti E, Fiorucci S. 2011. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta 1809(3):157-165.
94. Vore M, Liu Y, Huang L. 1997. Cholestatic properties and hepatic transport of steroid glucuronides. Drug Metab Rev 29(1-2):183-203.
95. Eurenius K, Dalton TV, Lokey HJ, McIntyre OR. 1969. The mechanism of glucocorticoid action on the phytohemagglutinin-stimulated lymphocyte. I. In vitro binding of corticosteroids to lymphoid tissue. Biochim Biophys Acta 177(3):572-578.
96. Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, Coleman R, Roma MG. 2003. Estradiol-17beta-d-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol 285(2):G449-G459.
97. Mottino AD, Crocenzi FA, Pozzi EJ, Veggi LM, Roma MG, Vore M. 2005. Role of microtubules in estradiol-17beta-D-glucuronide-induced alteration of canalicular Mrp2 localization and activity. Am J Physiol Gastrointest Liver Physiol 288(2):G327-G336.
98. Mottino AD, Cao J, Veggi LM, Crocenzi F, Roma MG, Vore M. 2002. Altered localization and activity of canalicular Mrp2 in estradiol-17beta-d-glucuronide-induced cholestasis. Hepatology 35(6):1409-1419.
99. Dawson ER, Platt BS. 1928. The phosphate ion and hydrolysis by pancreatic lipase. J Gen Physiol 11(4):357-360.
100. Boaglio AC, Zucchetti AE, Sanchez Pozzi EJ, Pellegrino JM, Ochoa JE, Mottino AD, Vore M, Crocenzi FA, Roma MG. 2010. Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17beta-d-glucuronide-induced cholestasis: Complementarity with classical protein kinase C. Hepatology 52(4):1465-1476.
101. Barosso IR, Zucchetti AE, Boaglio AC, Larocca MC, Taborda DR, Luquita MG, Roma MG, Crocenzi FA, Sanchez Pozzi EJ. 2012. Sequential activation of classic PKC and estrogen receptor alpha is involved in estradiol 17ss-d-glucuronide-induced cholestasis. PLoS ONE 7(11):e50711.
102. Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M. 2006. Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. J Biol Chem 281(24):16625-16631.
103. Ruiz ML, Rigalli JP, Arias A, Villanueva S, Banchio C, Vore M, Mottino AD, Catania VA. 2012. Induction of hepatic multidrug resistance associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor. Drug Metab Dispos 41(2):275-280.
104. Trauner M, Fickert P, Stauber RE. 1999. Inflammation-induced cholestasis. J Gastroenterol Hepatol 14(10):946-959.
105. Moseley RH. 1997. Sepsis-associated cholestasis. Gastroenterology 112(1):302-306.
106. Aoki M, Nakajima M, Hoshi Y, Saso N, Kato S, Sugiyama Y, Sato H., 2008. Effect of aminoguanidine on lipopolysaccharide-induced changes in rat liver transporters and transcription factors. Biol Pharm Bull 31(3):412-410.
107. Aitken AE, Richardson TA, Morgan ET. 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46: 123-149.
108. Zinchuk V, Zinchuk O, Okada T. 2005. Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: A quantitative colocalization study. Microsc Res Tech 67(2):65-70.
109. Kubitz R, Wettstein M, Warskulat U, Haussinger D. 1999. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 116(2):401-410.
110. Denson LA, Auld KL, Schiek DS, McClure MH, Mangelsdorf DJ, Karpen SJ. 2000. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J Biol Chem 275(12):8835-8843.
111. Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. 2004. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucl Recept 2(1):4.
112. Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ. 1998. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest 101(10):2092-2100.
113. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. 2003. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38(6):717-727.
114. Kojima H, Nies AT, Konig J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D. 2003. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 39(5):693-702.
115. Congiu M, Mashford ML, Slavin JL, Desmond PV. 2009. Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease. J Gastroenterol Hepatol 24(6):1038-1044.
116. Levy C, Lindor KD. 2003. Drug-induced cholestasis. Clin Liver Dis 7(2):311-330.
117. Mohi-ud-din R, Lewis JH. 2004. Drug- and chemical-induced cholestasis. Clin Liver Dis 8(1):95-132, vii.
118. Chitturi S, Farrell GC. 2001. Drug-induced cholestasis. Semin Gastrointest Dis 12(2):113-124.
119. Hamilton JP, Laurin JM. 2008. Drug-induced cholestasis. Totowa, New Jersey: Humana Press Inc.
120. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T. 2012. Mitigating the inhibition of human bile salt export pump by drugs: Opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab Dispos 40(12):2332-2341.
121. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD. 2000. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 57(1):24-35.
122. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV. 2001. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology 33(5):1223-1231.
123. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. 2002. The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors. Gastroenterology 123(5):1649-1658.
124. Wang EJ, Casciano CN, Clement RP, Johnson WW. 2003. Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: Evidence for contingent unequal binding sites. Pharm Res 20(4):537-544.
125. Hirano H, Kurata A, Onishi Y, Sakurai A, Saito H, Nakagawa H, Nagakura M, Tarui S, Kanamori Y, Kitajima M, Ishikawa T. 2006. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 3(3):252-265.
126. Zhu X, Sedykh A, Zhu H, Liu S, Tropsha S. 2013. The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein binding. Pharm Res. [Epub ahead of print.]
127. Benet LZ, Broccatelli F, Oprea TI. 2011. BDDCS applied to over 900 drugs. AAPS J 13(4):519-547.
128. Olah M, Rad R, Ostopovici L, Bora A, Hadaruga R, Hadaruga D, Moldovan R, Fulias A, Mracec M, Opre TI. 2007. WOMBAT and WOMBAT-PK: Bioactivity databases for lead and drug discovery. In Chemical biology: From small molecules to systems biology and drug design; Schreiber SL, Kapoor TM, Wess G, Eds. New York: Wiley-VCH, pp 760-786.
129. van Staden CJ, Morgan RE, Ramachandran B, Chen Y, Lee PH, Hamadeh HK. 2012. Membrane vesicle ABC transporter assays for drug safety assessment. Curr Protoc Toxicol Chapter 23:Unit 23 25.
130. Modica S, Gadaleta RM, Moschetta A. 2010. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 8:e005.
131. Goodwin B, Kliewer SA. 2002. Nuclear receptors. I. Nuclear receptors and bile acid homeostasis. Am J Physiol Gastrointest Liver Physiol 282(6):G926-G931.
132. Saito H, Osumi M, Hirano H, Shin W, Nakamura R, Ishikawa T. 2009. Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP). AAPS J 11(3):581-589.
133. Ng C, Xiao YD, Lum BL, Han YH. 2005. Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2). Eur J Pharm Sci 26(5):405-413.
134. Pedersen JM, Matsson P, Bergstrom CA, Norinder U, Hoogstraate J, Artursson P. 2008. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 51(11):3275-3287.
135. Zhang H, Xiang ML, Zhao YL, Wei YQ, Yang SY. 2009. Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors. Eur J Pharm Sci 36(4-5):451-457.
136. Sedykh A, Fourches D, Duan J, Hucke O, Garneau M, Zhu H, Bonneau P, Tropsha A. 2012. Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res 30(4):996-1007.
137. Gonzalez PM, Acharya C, Mackerell AD, Jr., Polli JE. 2009. Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. Pharm Res 26(7):1665-1678.
138. Zheng X, Ekins S, Raufman JP, Polli JE. 2009. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm 6(5):1591-1603.
139. Zheng X, Pan Y, Acharya C, Swaan PW, Polli JE. 2010. Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid. Bioconjug Chem 21(11):2038-2048.
140. Rais R, Acharya C, Mackerell AD, Polli JE. 2010. Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol Pharm 7(6):2240-2254.
141. Rais R, Acharya C, Tririya G, Mackerell AD, Polli JE. 2010. Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter. J Med Chem 53(12):4749-4760.
142. Greupink R, Nabuurs SB, Zarzycka B, Verweij V, Monshouwer M, Huisman MT, Russel FG. 2012. In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity. Toxicol Sci 129(1):35-48.
143. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P. 2012. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): Influence of protein expression on drug-drug interactions. J Med Chem 55(10):4740-4763.
144. Karlgren M, Ahlin G, Bergstrom CA, Svensson R, Palm J, Artursson P. 2012. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res 29(2):411-426.
145. Akanuma S, Uchida Y, Ohtsuki S, Kamiie J, Tachikawa M, Terasaki T, Hosoya K. 2011. Molecular-weight-dependent, anionic-substrate-preferential transport of beta-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab Pharmacokinet 26(6):602-611.
146. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
147. Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, Krasowski MD. 2009. Challenges predicting ligand-receptor interactions of promiscuous proteins: The nuclear receptor PXR. PLoS Comput Biol 5(12):e1000594.
148. Kortagere S, Krasowski MD, Ekins S. 2012. Ligand- and structure-based pregnane X receptor models. Methods Mol Biol 929:359-375.
149. Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, Ekins S. 2008. Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21(7):1457-1467.
150. Kortagere S, Chekmarev D, Welsh WJ, Ekins S. 2009. Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res 26(4):1001-1011.
151. Honorio KM, Garratt RC, Polikarpov I, Andricopulo AD. 2007. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. J Mol Graph Model 25(6):921-927.
152. Zhang T, Zhou JH, Shi LW, Zhu RX, Chen MB. 2007. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. Bioorg Med Chem Lett 17(8):2156-2160.
153. Matter H, Anger LT, Giegerich C, Gussregen S, Hessler G, Baringhaus KH. 2012. Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules. Bioorg Med Chem 20(18):5352-5365.
154. Ung CY, Li H, Yap CW, Chen YZ. 2007. In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 71(1):158-168.
155. Dybdahl M, Nikolov NG, Wedebye EB, Jonsdottir SO, Niemela JR. 2012. QSAR model for human pregnane X receptor (PXR) binding: Screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity. Toxicol Appl Pharmacol 262(3):301-309.
156. Honorio KM, Garratt RC, Andricopulo AD. 2005. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators. Bioorg Med Chem Lett 15(12):3119-3125.
157. Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, Souchet M, Auwerx J, Saladin R, Wagner A. 2010. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes. J Med Chem 53(1):178-190.
158. Schuster D, Markt P, Grienke U, Mihaly-Bison J, Binder M, Noha SM, Rollinger JM, Stuppner H, Bochkov VN, Wolber G. 2011. Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation. Bioorg Med Chem 19(23):7168-7180.
159. Grienke U, Mihaly-Bison J, Schuster D, Afonyushkin T, Binder M, Guan SH, Cheng CR, Wolber G, Stuppner H, Guo DA, Bochkov VN, Rollinger JM. 2011. Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum. Bioorg Med Chem 19(22):6779-6791.
160. Diaz Ochoa JG, Bucher J, Pery AR, Zaldivar Comenges JM, Niklas J, Mauch K. 2012. A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk. Front Pharmacol 3:204.
161. Howell BA, Yang Y, Kumar R, Woodhead JL, Harrill AH, Clewell HJ, 3rd, Andersen ME, Siler SQ, Watkins PB. 2012. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym: A mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn 39(5):527-541.